Revance Therapeutics, Inc. is a privately held specialty biopharmaceutical company that has developed the proprietary TransMTSTM platform technology which enables local, targeted delivery of large macromolecules across skin. The lead investigational product, RT001 Botulinum Toxin Type A Topical Gel, has demonstrated safety and statistically significant efficacy in Phase 2 clinical trials.
Revance is also developing a next generation injectable botulinum toxin type A product (RT002) integrating the TransMTS technology with the neurotoxin to improve onset of action, increase duration of effect, and limit diffusion away from treatment site. The company manufactures and has exclusive, worldwide rights to a family of purified, well characterized botulinum toxin molecules that could potentially be used across a range of therapeutic indications including migraine, rhinitis and other disease states for which botulinum toxin is an appropriate treatment.
Revance Therapeutics, Inc. in the News